7SS Stock Chart & Stats
€0.19
<€0.01(7.63%)
At close: 4:00 PM EST
€0.19
<€0.01(7.63%)
Day’s Range― - ―
52-Week Range€0.10 - €0.26
Previous CloseN/A
Volume0.00
Average Volume (3M)248.00
Market Cap
€80.86M
Enterprise Value-€1.19K
Total Cash (Recent Filing)€1.94B
Total Debt (Recent Filing)€8.93M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding734,577,100
10 Day Avg. Volume8
30 Day Avg. Volume248
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthVery low leverage and positive equity across 2021–2025 give Brii durable financial flexibility. This cushion reduces short-term solvency risk, supports continued R&D and commercialization spending, and allows management to pursue partnerships or milestones without immediate forced financing under stress.
Partnering/licensing Business ModelA commercialization and partnering-based model lowers capital intensity versus fully internal development and provides multiple non-linear revenue channels (milestones, royalties, profit-share). Structurally this can scale returns if partners succeed and reduces upfront R&D capital burden over the medium term.
Reduced Cash Burn In 2025Smaller losses and reduced cash burn in 2025 signal improving operating discipline or cost structure adjustments. If sustained, this trend can extend runway, lower near-term financing needs and improve chances of executing commercialization milestones without materially increasing leverage or diluting equity.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicate the business still consumes cash to fund operations. Over the medium term this forces reliance on external funding or available liquidity, raising dilution or refinancing risk and limiting the company's ability to invest in scaling commercialization independently.
Sustained Losses And Revenue ContractionDeep negative margins and a material revenue decline in 2025 show the company has not yet achieved scalable commercial traction. Persisting losses erode returns on equity and hinder the firm's ability to leverage fixed costs, making a durable path to profitability uncertain without sustained revenue recovery.
Dependence On Partner PerformanceHeavy reliance on in-licensed products, milestones and partner commercialization creates structural revenue timing and concentration risk. Revenue and cash flow can swing with third-party approvals, sales execution or milestone timing, reducing predictability of long-term cash generation and strategic independence.
Brii Biosciences Limited News
7SS FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was €0.10 and its highest was €0.26 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is €80.86M.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Aug 20, 2026 which is in 26 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Mar 19, 2026. The company reported -€0.004 earnings per share for the quarter, beating the consensus estimate of -€0.008 by €0.004.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate is -0.01.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 734,577,100 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -€0.004 in its last earnings report, beating expectations of -€0.008. Following the earnings report the stock price went down -4.43%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in DE:7SS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brii Biosciences Limited
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Technical Analysis
Mabpharm Limited
―
Clover Biopharmaceuticals Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Transcenta Holding Limited
―
AIM Vaccine Co., Ltd. Class H
―